Platform Modernization: How to Build the Business Case

Why the investment that never fits a budget category keeps losing, and what to put in front of finance instead

Budgets run annually. Architecture consequences run five to seven years.

Every R&D leader in medtech understands this, and almost no planning process accounts for it. A platform decision made this quarter will shape what your product line can and cannot do into the next decade, but it has to survive a funding conversation built around the next twelve months. That mismatch is the reason so many companies know exactly what they need to modernize and cannot get it approved.

If you are in the middle of FY27 planning right now, this is the conversation I would want to have with you.

Why modernization loses every year

Most R&D portfolios sort into three categories. Incremental work that improves what exists. Sustaining work that keeps products in market. Breakthrough work that opens something new. Every one of those has a champion, a milestone, and a line you can point to.

Platform modernization is none of the three. It is the foundation the other three run on, which means it does not launch a product, does not hit a submission date, and carries no revenue of its own. So it competes against programs that have all three, and it loses. Then it costs more next year.

Deloitte’s 2026 Global Technology Leadership Study, drawn from more than 660 technology executives, estimates that technical debt now absorbs somewhere between 21 and 40 percent of an organization’s total technology spend. That is not a rounding error. It is a third of the budget servicing decisions made years ago, and almost none of it appears as a line item anyone reviews.

Meanwhile, the money is getting tighter. Aggregate R&D spending across the Medtech Big 100 grew less than 1 percent in the most recent analysis, after 10 percent the year before and 20 percent the year before that. Twenty-three of those companies cut R&D outright. The environment is not going to hand you a modernization budget. You have to build the case for it.

What finance will actually fund

The mistake I see most often is a business case written in engineering language and handed to people who do not speak it. Interoperability, containerization, and codebase consolidation are real, but they are not decision inputs for a CFO. 

Four things are.

1. Derivative launch cost. What does the next product in the family cost today, on the current foundation, versus on a modern one? If your second and third devices in a platform each require substantial rework because nothing was designed to extend, that delta is your case. It is also the number nobody has ever calculated.
2. Verification cost per release. V&V is not a one-time expense. It recurs on every change, and on a fragmented architecture it recurs badly. A modernization that reduces the verification surface pays back on every release for the life of the platform, and that is a recurring line finance already tracks.
3. Risk, priced honestly. Cybersecurity remediation on legacy code. Component obsolescence with no supported migration path. A supply chain change you cannot absorb because the architecture will not flex. Each of these has a probability and a cost. Putting real numbers on them turns a vague concern into a quantified exposure, which is a conversation the board already knows how to have.
4. Optionality. This is the one that lands hardest and gets used least. Optionality is the capability you cannot add today at any price, on any timeline, because the foundation will not support it. If a competitor ships connected data capture next year and your answer is eighteen months of rearchitecture first, you did not lose on engineering talent. You lost on a platform decision made years earlier.

Price the alternative, not just the investment

Most business cases price the ask. The stronger move is pricing the thing you are choosing instead.

Deferral is a decision, and it has a cost that compounds. Every device added to an aging architecture increases the eventual remediation scope. Every year of delay raises the cost of the same work. Every new regulatory obligation lands on a foundation that is less able to absorb it.

So put both columns in front of your executive team. Here is the investment. Here is what three more years of deferral costs, in derivative launch delay, in verification overhead, in risk exposure that grows rather than holds steady. When leadership can see both, the conversation stops being about whether to spend and becomes about when. That is a much better argument to be having.

Sequence it, do not tear it down

One caution, because this is where these proposals often lose credibility. A modernization case that reads as rip-and-replace will not survive contact with a leadership team that has active programs and committed launch dates. Nor should it.

The teams that get this right treat it as a sequencing problem rather than a binary one. What has to be addressed now to protect future optionality. What can be stabilized and carried forward as-is. What can genuinely wait. Framed that way, modernization runs alongside active development instead of interrupting it, and the ask becomes a staged investment rather than a program-stopping event.

That framing also happens to be more honest. Very few medtech companies need to replace everything. Most need to fix the two or three architectural decisions that are quietly capping what the roadmap can contain.

The question for FY27

Not whether your platform needs work. You already know the answer to that.

The question is whether you can put a number on what deferring it costs, and whether that number is in front of the person who decides. If it is not, the investment will lose again this year, for the same reason it lost last year, and the case will be more expensive to make in FY28.

Suntra MedTech Solutions works at the architectural level inside FDA Class II and III environments, guiding clients from legacy platforms to modern, AI-ready systems across multi-language, multi-device portfolios. Start the conversation at SuntraMedTech.com/contact.

Sources

Medical Design & Outsourcing, “R&D alert: Research and development spending stalls in the 2025 Medtech Big 100 ranking,” September 2025, updated April 2026. https://www.medicaldesignandoutsourcing.com/rd-alert-research-and-development-spending-medtech-big-100/doutsourcing.com/rd-alert-research-and-development-spending-medtech-big-100/

Deloitte, 2026 Global Technology Leadership Study. https://www.deloitte.com/us/en/insights/topics/technology-management/technical-debt-impact.html